Abstract

*Khadija Benchekroun, Najlae Elghorfi, Sawsane Razine, Siham Lemsaness, Dr. Saad Lannaz, Dr. Hounayda Jerguigue, Pr Rachida Latib, Pr Youssef Omor, Pr Saber Boutayeb, Pr Hind M’rabti, Pr Ibrahim Elghissassi and Pr Hassan Errihani

ABSTRACT

Background: Medulloblastoma is a malignant embryonal tumor that commonly arises in the cerebellum. While it is the most common central nervous system malignancy in children, it is significantly less common among adults. Although surgery and radiotherapy are considered as therapeutic standards of medulloblastoma, addition of adjuvant chemotherapy is controversial. In a palliative situation, the place of chemotherapy is constantly progressing. Case report: We present a case of a 34-year-old patient with cerebellar vermis medulloblastoma. The patient underwent a subtotal resection which was classified as non WNT classic histology. Due to the persistence of a large tumor residue, postoperative radiotherapy was added followed by adjuvant chemotherapy. Despite a well-conducted treatment, the patient presented with a local tumor recurrence for which he was indicated to receive palliative chemotherapy. Conclusion: Addition of adjuvant chemotherapy can lead to better outcomes in adult patients with medulloblastoma. The recurrence of medulloblastoma after postoperative radiotherapy and chemotherapy is not very common, and the decision of therapeutic choice can be elaborate given the limited data currently available.